Therapeutics & Glooko Partner: Advancing AspyreRx For Type 2 Diabetes In The U.S.
Better Therapeutics Inc. (BTTX) and Glooko, Inc. have
announced a strategic partnership to integrate Better Therapeutics' AspyreRx™
digital behavioral treatment for type 2 diabetes (T2D) into Glooko's diabetes
management platform. The collaboration enables U.S. healthcare providers using
Glooko to identify suitable patients for AspyreRx, prescribe the digital
therapeutic, and monitor patients throughout their treatment journey. Glooko's
solutions have assisted over 3.4 million individuals with diabetes in the U.S.
and are utilized in nearly 5,000 clinic locations. AspyreRx will now be
accessible on Glooko's healthcare provider platform as a new treatment option.
Leveraging Glooko's 'precision engagement,' patients eligible for AspyreRx will
be identified for healthcare providers. This strategic alliance aims to enhance
patient outcomes and streamline the management of T2D within the Glooko
network. Russ Johannesson, CEO of Glooko, expressed enthusiasm about the
partnership, emphasizing its potential to offer healthcare providers a valuable
new treatment option for managing patients with T2D.
Comments
Post a Comment